Objective. To evaluate and compare HER2/neu protein overexpression and gene amplification in uterine serous papillary endometrial cancer (USPC). Study design. Immunohistochemical (IHC) and fluorescent in situ hybridiz...Objective. To evaluate and compare HER2/neu protein overexpression and gene amplification in uterine serous papillary endometrial cancer (USPC). Study design. Immunohistochemical (IHC) and fluorescent in situ hybridization (FISH) assays were used to analyze and compare HER2/neu protein expression and gene amplification, respectively, in paraffin blocks from 26 women harboring stage IA to IV USPC treated at the University of Arkansas for Medical Sciences from 1997 to 2004. Chromosome 17 polysomy status by FISH was also assessed in all specimens. Results. Moderate-to-strong expression of HER2/neu protein was noted in 16 (62% ) of 26 USPC samples evaluated, with 7 (27% ) samples showing moderate staining (2? ) and 9 (35% ) showing strong staining (3? ) for HER2/neu. Amplification of the ERBB2 gene by FISH was observed in 11 of the 26 (42% ) cases. Protein overexpression and gene amplification were found to correlate in 100% (9 of 9) of the 3? positive tumors and 2 out of 7 (29% ) of the 2? positive tumors. Heterogeneity was noted in 3 cases in the amplification of the HER2/neu gene within the same tumor samples with pockets of amplified tumor cells amidst nonamplified tumor cells. None of the 10 USPC cases scored by IHC as 0 or 1? was found positive for ERBB2 amplification by FISH. Conclusions. Amplification of the HER2/neu oncogene represents a common finding in USPC. FISH analysis should be used for confirmation of gene amplification in USPC showing 2? expression of HER2/neu. Prior screening and selection of appropriate immunohistochemistry-positive areas may be beneficial in the selection of some USPC patients undergoing FISH analysis.展开更多
目的:对比结肠癌患者接受单孔加一腹腔镜手术(Single-Incision Plus One Port Laparoscopic Surgery,SILS+1)与常规5孔腹腔镜手术的治疗效果。方法:收集2021年3月~2022年2月在本院胃肠外科接受结肠癌根治术患者为研究对象,根据手术方式...目的:对比结肠癌患者接受单孔加一腹腔镜手术(Single-Incision Plus One Port Laparoscopic Surgery,SILS+1)与常规5孔腹腔镜手术的治疗效果。方法:收集2021年3月~2022年2月在本院胃肠外科接受结肠癌根治术患者为研究对象,根据手术方式将其分为观察组(接受SILS+1,n=53)和对照组(接受5孔腹腔镜手术,n=55);首先分析比较两种手术方法围手术期指标和实验室如白蛋白、总蛋白、C-反应蛋白(C-reactive protein,CRP)等;再比较两组术后数字疼痛强度量表(numerical rating scale,NRS)评分,并发症和随访结果。结果:两组术中出血量、淋巴结清扫数量和pTNM分期、首次进食时间无差异(P>0.05);接受SILS+1患者首次下床、排气、住院时间均低于对照组,手术时间长于对照组(P<0.05);两组患者术前总蛋白、白蛋白、去甲肾上腺素(Norepinephrine,NE)、CRP、白细胞介素-6(Interleukin-6,IL-6)水平无差异(P>0.05),术后总蛋白、白蛋白较术前下降,CRP、IL-6、NE较术前升高(P<0.05),组间差异显著(P<0.05);术后第12、24、48h的NRS评分,观察组均低于对照组(P<0.05);观察组和对照组并发症发生率(3.77%,5.45%)、2年总生存率(94.33%,92.72%)和复发率(21.56%,23.63%),相比无统计学差异(P>0.05)。结论:与常规5孔腹腔镜手术相比,SILS+1在结肠癌根治术中具备术后康复快、痛感低、炎症反应轻和住院时间短等优势,长期疗效与传统腹腔镜手术(CLS)相比无差异。展开更多
文摘Objective. To evaluate and compare HER2/neu protein overexpression and gene amplification in uterine serous papillary endometrial cancer (USPC). Study design. Immunohistochemical (IHC) and fluorescent in situ hybridization (FISH) assays were used to analyze and compare HER2/neu protein expression and gene amplification, respectively, in paraffin blocks from 26 women harboring stage IA to IV USPC treated at the University of Arkansas for Medical Sciences from 1997 to 2004. Chromosome 17 polysomy status by FISH was also assessed in all specimens. Results. Moderate-to-strong expression of HER2/neu protein was noted in 16 (62% ) of 26 USPC samples evaluated, with 7 (27% ) samples showing moderate staining (2? ) and 9 (35% ) showing strong staining (3? ) for HER2/neu. Amplification of the ERBB2 gene by FISH was observed in 11 of the 26 (42% ) cases. Protein overexpression and gene amplification were found to correlate in 100% (9 of 9) of the 3? positive tumors and 2 out of 7 (29% ) of the 2? positive tumors. Heterogeneity was noted in 3 cases in the amplification of the HER2/neu gene within the same tumor samples with pockets of amplified tumor cells amidst nonamplified tumor cells. None of the 10 USPC cases scored by IHC as 0 or 1? was found positive for ERBB2 amplification by FISH. Conclusions. Amplification of the HER2/neu oncogene represents a common finding in USPC. FISH analysis should be used for confirmation of gene amplification in USPC showing 2? expression of HER2/neu. Prior screening and selection of appropriate immunohistochemistry-positive areas may be beneficial in the selection of some USPC patients undergoing FISH analysis.
文摘目的:对比结肠癌患者接受单孔加一腹腔镜手术(Single-Incision Plus One Port Laparoscopic Surgery,SILS+1)与常规5孔腹腔镜手术的治疗效果。方法:收集2021年3月~2022年2月在本院胃肠外科接受结肠癌根治术患者为研究对象,根据手术方式将其分为观察组(接受SILS+1,n=53)和对照组(接受5孔腹腔镜手术,n=55);首先分析比较两种手术方法围手术期指标和实验室如白蛋白、总蛋白、C-反应蛋白(C-reactive protein,CRP)等;再比较两组术后数字疼痛强度量表(numerical rating scale,NRS)评分,并发症和随访结果。结果:两组术中出血量、淋巴结清扫数量和pTNM分期、首次进食时间无差异(P>0.05);接受SILS+1患者首次下床、排气、住院时间均低于对照组,手术时间长于对照组(P<0.05);两组患者术前总蛋白、白蛋白、去甲肾上腺素(Norepinephrine,NE)、CRP、白细胞介素-6(Interleukin-6,IL-6)水平无差异(P>0.05),术后总蛋白、白蛋白较术前下降,CRP、IL-6、NE较术前升高(P<0.05),组间差异显著(P<0.05);术后第12、24、48h的NRS评分,观察组均低于对照组(P<0.05);观察组和对照组并发症发生率(3.77%,5.45%)、2年总生存率(94.33%,92.72%)和复发率(21.56%,23.63%),相比无统计学差异(P>0.05)。结论:与常规5孔腹腔镜手术相比,SILS+1在结肠癌根治术中具备术后康复快、痛感低、炎症反应轻和住院时间短等优势,长期疗效与传统腹腔镜手术(CLS)相比无差异。
